Another example of an AR-targeting PROTAC is ARV-110, which is composed of enzalutamide (a non-steroid AR antagonist which is used in the treatment of castration-resistant prostate cancer) linked to a thalidomide derivative. This evidence concerns the gene AR and prostate carcinoma.